<DOC>
	<DOCNO>NCT00021736</DOCNO>
	<brief_summary>The purpose study determine whether anti-VEGF drug effective stabilizing and/or improve vision patient wet form AMD</brief_summary>
	<brief_title>Phase II/III Study Anti-VEGF Neovascular AMD</brief_title>
	<detailed_description>This randomize , double-masked , control , dose-ranging , multi-center comparative trial , parallel group . Patients stratify clinical center , percentage classic CNV vessel : [ predominantly classic ( &gt; 50 % ) vs. minimally classic ( 1-49 % ) vs. purely occult ( 0 % ) ] , accord whether , , receive prior PDT Visudyne ( ) . All patient re-randomized 54 week treatment either , continue discontinue therapy 48 week .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients either gender , age 50 year , diagnose subfoveal CNV secondary AMD best correct visual acuity 20/40 20/320 absence subfoveal atrophy scar study eye , good equal 20/800 fellow eye , may enrol . Clinically significant concomitant disease exclude .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>choroidal neovascularization ( CNV )</keyword>
	<keyword>subretinal neovascularization</keyword>
</DOC>